Medtronic
MDT
2,023 hedge funds and large institutions have $96.1B invested in Medtronic in 2022 Q2 according to their latest regulatory filings, with 115 funds opening new positions, 856 increasing their positions, 806 reducing their positions, and 165 closing their positions.
94% more call options, than puts
Call options by funds: $920M | Put options by funds: $474M
6% more repeat investments, than reductions
Existing positions increased: 856 | Existing positions reduced: 806
0.09% more ownership
Funds ownership: 80.51% → 80.59% (+0.09%)
4% less funds holding
Funds holding: 2,100 → 2,023 (-77)
18% less funds holding in top 10
Funds holding in top 10: 39 → 32 (-7)
20% less capital invested
Capital invested by funds: $120B → $96.1B (-$23.6B)
30% less first-time investments, than exits
New positions opened: 115 | Existing positions closed: 165
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$433M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$406M |
| 3 |
Morgan Stanley
New York
|
+$256M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$250M |
| 5 |
BlackRock
New York
|
+$242M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$795M |
| 2 |
Lazard Asset Management
New York
|
-$599M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$513M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$391M |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$200M |
MDT Hedge Fund Activity: Q2 2022 in Review
2,023 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Medtronic (MDT) for Q2 2022, worth a combined $96.1B — down 20% from $120B a quarter earlier.
Sellers outnumbered buyers: 165 funds closed out of MDT and 115 opened new positions — a net loss of 50 holders — while 806 trimmed existing stakes and 856 added.
The largest buyer was Barclays, adding an estimated $433M. The largest seller was T. Rowe Price Associates, cutting an estimated $795M.
- 2,023 institutional investors held Medtronic (MDT) as of Q2 2022, down from 2,100 in Q1 2022.
- Funds reported $96.1B of Medtronic stock for Q2 2022, down 20% quarter-over-quarter.
- 115 funds opened new Medtronic positions in Q2 2022 and 165 closed out, a net change of -50 holders.
- The largest Medtronic buyer in Q2 2022 was Barclays, an estimated $433M added.
- The largest Medtronic seller in Q2 2022 was T. Rowe Price Associates, an estimated $795M sold.
Based on aggregated 13F filings for Q2 2022.